Synthesis, docking and anticancer evaluation of new pyridine-3-carbonitrile derivatives.

Abstract

N’-(2-((4-(Benzo[d][1, 3]dioxol-5-yl)-3-cyano-6-(naphthalen-2-yl)-pyridin-2-yl)oxy)- acetyl)benzohydrazide (6) and hydrazide derivatives (7–10) were synthesized via reaction of 3-cyano-pyridinacetohydrazide (5) with benzoylchloride and the appropriate aldehyde, respectively. Also, 4-(Benzo[d][1, 3]dioxol-5-yl)-2-(2- (3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethoxy)-6-(naphthalen-2- yl) nicotinonitrile (11) was prepared through reaction of (5) with ethylace toacetate. In addition, the hydrazide 5 was used as a starting material for synthesizing other nicotinonitrile derivatives (12, 13) and acetohydrazides (14, 15). Moreover, new 2, 5-disubsitituted-1,3,4-oxadiazoles (16, 17) were furnished by the reaction of (5) with benzoic acid derivatives. The cytotox icity for some new compounds was investigated against human breast cancer MCF-7 and MDA-MB-231 cell lines at concentrations (0, 10, 20, 40, 60, 80, and 100 lg/ml) using MTT assay. Compounds (4, 9, 14 and 17) were recorded the lowest half-maximal inhibitory concentrations (IC50s) against MCF-7 and MDA-MB-231 cell lines via cytotoxicity assays. These results were confirmed using molecular docking experiments. From the previous observations, we suggested that our synthesized compounds could be of great potential against breast cancer cells